Bayer collaborates with Gubra to unleash peptide potential
A drug candidate developed by Danish firm Gubra has caught Bayer's eye, so the parties are now collaborating to bring it to market. Bayer will pay millions of dollars in milestone payments, if the candidate performs.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY CATHERINE BRETT
Bayer, which is one of the world's largest pharmaceutical companies, has become the latest partner of contract research and biotech company Gubra.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
